Dendreon, the Seattle developer of immune-boosting therapies for cancer, said today in its second-quarter financial report that it had $287 million in cash and investments at the end of June. The company (NASDAQ: [[ticker:DNDN]]) had total operating expenses in the second quarter of $20.9 million, as it continues to prepare its application to seek FDA approval of its first product, sipuleucel-T (Provenge) for men with terminal prostate cancer. Dendreon raised $221 million earlier this year, and is investing it in expanding manufacturing capacity at its existing facility in Morris Plains, NJ, and at new plants in the Atlanta area, and in Orange County, CA.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
